Superior innovation designed for women
The movement starts here
Our Mission
Femasys is a biomedical company aiming to meet women’s needs worldwide with a novel suite of product candidates that include minimally invasive, in-office technologies for reproductive health.
Our Focus
Infertility
In the US alone, more than 10 million women struggle with infertility. Despite advancements, there have been no new affordable options for women struggling with infertility in over 30 years.
Permanent birth control
Over 13 million women in the US no longer intend to have children. Surgical tubal ligation has been performed since the 1880’s and remains the only option for women who want permanent birth control.
Clinical-Stage Assets
Commercial Assets
FemVue® is a diagnostic tool that provides safe and reliable contrast for ultrasound evaluation of the fallopian tubes. FemVue is available for commercial use in the US, Japan, and other major countries.
FemCath™ allows for assessment of the uterine cavity and, when paired with FemVue, selective evaluation of the fallopian tubes.
FemCerv® is a diagnostic tool to capture a comprehensive sample of the cervix for evaluation of cervical cancer. FemCerv is available for commercial use in the US.
Press Releases
12/19/2022 09:00:00
Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device
Read More »12/12/2022 08:30:00
Femasys Inc. Reports Encouraging Promotional Launch of FemCerv at AAGL Based on Positive Reception by Gynecologic Physicians and Surgeons
Read More »11/29/2022 07:00:00